Scientific intelligence record
Experience 2.0
Long-acting GHRH analog
Also known as: CJC1295, CJC-1295 DAC, Drug Affinity Complex GRF
CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.
Record status
Traceability partial
Last meaningful update: 9/8/2026
Ranked research corpus
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
36 matching records · ranked 2026-09-18
Page 1 of 2
WPF seed · 2026 · PMID 41880199 · DOI 10.23736/S0022-4707.26.17773-1
laboratory-mechanistic
WPF seed · 2026 · PMID 41138283 · DOI 10.1016/j.jpba.2025.117207
laboratory-mechanistic
Europe PMC · 2026 · Source ID doi:10.20944/preprints202604.1748.v1 · DOI 10.20944/preprints202604.1748.v1
preclinical-animal
WPF seed · 2026 · PMID 41476424 · DOI 10.1177/03635465251357593
laboratory-mechanistic
WPF seed · 2026 · PMID 42160466 · DOI 10.2106/JBJS.RVW.26.00027
laboratory-mechanistic
WPF seed · 2026 · PMID 42578445 · DOI 10.1177/03635465261464420
laboratory-mechanistic
Europe PMC · 2026 · Source ID doi:10.20944/preprints202512.1011.v3 · DOI 10.20944/preprints202512.1011.v3
preclinical-animal
WPF seed · 2026 · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
human-interventional
Europe PMC · 2026 · PMID 42395176 · DOI 10.3389/fendo.2026.1822475
human-interventional
WPF seed · 2026 · PMID 42123471 · DOI 10.3390/ijms27093890
laboratory-mechanistic
WPF seed · 2026 · PMID 41490200 · DOI 10.5435/JAAOSGlobal-D-25-00236
laboratory-mechanistic
Europe PMC · 2026 · PMID 42021992 · DOI 10.3389/fragi.2026.1790247
human-interventional
Europe PMC · 2025 · Source ID doi:10.20944/preprints202512.1011.v1 · DOI 10.20944/preprints202512.1011.v1
preclinical-animal
WPF seed · 2024 · PMID 38197510 · DOI 10.1002/jms.4996
laboratory-mechanistic
WPF seed · 2023 · PMID 37806509 · DOI 10.1016/j.ab.2023.115336
laboratory-mechanistic
WPF seed · 2022 · PMID 35298973 · DOI 10.1016/j.jpba.2022.114726
laboratory-mechanistic
WPF seed · 2022 · PMID 34736642 · DOI 10.1016/j.talanta.2021.122905
laboratory-mechanistic
WPF seed · 2022 · PMID 38716080 · DOI 10.1002/ansa.202200027
laboratory-mechanistic
WPF seed · 2021 · PMID 34665524 · DOI 10.1002/dta.3183
laboratory-mechanistic
WPF seed · 2020 · PMID 32971474 · DOI 10.1016/j.chroma.2020.461548
laboratory-mechanistic
WPF seed · 2019 · PMID 30938069 · DOI 10.1002/dta.2599
laboratory-mechanistic
WPF seed · 2019 · PMID 30489688 · DOI 10.1002/dta.2554
laboratory-mechanistic
WPF seed · 2016 · PMID 26771670 · DOI 10.3109/10826084.2015.1082595
laboratory-mechanistic
WPF seed · 2016 · PMID 26879649 · DOI 10.1007/s00216-016-9377-3
human-observational
WPF seed · 2016 · PMID 27710891 · DOI 10.1016/j.forsciint.2016.09.017
laboratory-mechanistic
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.
European Medicines Agency medicines databaseNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.
Drugs@FDA: FDA-Approved DrugsCJC-1295 evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
DAC-bearing molecule; it is not the distinct 29-residue no-DAC analog catalogued as PubChem CID 56841945.
Sources: NIH PubChem — CJC-1295, DAC-bearing · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). CJC-1295 — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/cjc-1295
AMA / Vancouver
World Peptide Foundation. CJC-1295 — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/cjc-1295
36
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
4
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
36
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
4
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
CJC-1295 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
The chemistry record exists, but no displayable molecular fields have been entered yet.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2006 · study · Temporal status not established
peer_reviewed_research
2006 · study · Temporal status not established
peer_reviewed_research
2006 · study · Temporal status not established
peer_reviewed_research
2009 · study · Temporal status not established
peer_reviewed_research
2015 · study · Temporal status not established
peer_reviewed_research
2016 · study · Temporal status not established
peer_reviewed_research
2016 · study · Temporal status not established
peer_reviewed_research
2016 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2019 · study · Temporal status not established
peer_reviewed_research
2020 · study · Temporal status not established
peer_reviewed_research
2021 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2023 · study · Temporal status not established
peer_reviewed_research
2024 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
4 represented evidence records
Years represented: 2015, 2016, 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 2015, 2016, 2022, 2024
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2015, 2016
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2015, 2016
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 2006, 2009
Publishing organizations appearing in records: peer_reviewed_research
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 4 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the CJC-1295 evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/8/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/8/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:18 AM
25 of 36 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OBJECTIVE: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. DESIGN: The study design was two randomized, placebo-controlled, double-blind, …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295 …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The target analytes included Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin) as well as two metabolites of Geref and CJC-1293, which were captured from plasma samples using a polyclonal GHRH antibody in concert with protein A/G monolithic MSIA D.A …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. ...These findings demonstrate that treatment with once-daily admi …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The affinity profiles of CBD and carboxy-THC are significantly different from the profiles of synthetic GHR mimetics such as CJC-1295 or [D-Arg(1)-D-Phe(5)-D-Trp(7,9)-Leu(11)]-Substance P peptides, which are the most common interferents; the cannabinoids promoted th …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH(2), somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is abl …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OBJECTIVE: Our objective was to assess GH pulsatility after a single injection of CJC-1295 and determine which GH secretion parameters correlated to the increase in IGF-I production. METHODS: GH pulsatility was assessed by 20-min blood sampling during an overnight 1 …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary m …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A temporal analysis illustrates the stability of the most popular products as well as the emergence of new products such as peptides (e.g. CJC-1295). 327 suppliers were detected, mostly with dedicated websites or direct sales by e-mail as selling methods. ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland. ...Previously we described a screening procedure for the detection of CJC-1295 in equine plasma using an immuno-PCR assay. Here we demonstr …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
METHODS: A systematic Internet search was conducted using variation of the term "CJC-1295"; and combined with "forum." Ninety-six hits related to bodybuilding websites where CJC-1295 was mentioned. ...These were searched internally for reference to …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
With urine samples representing still the most frequently collected doping control specimens, efficient extraction of peptidic analytes from this matrix was a major goal of this method, as demonstrated for the included compounds such as insulins (human, lispro, aspart, glulisine, …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growt …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread a …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three indepe …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog. DESIGN: Sera from 11 healthy young adult men before and one week after CJC-1295 injection were analyze …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This study investigates the in vitro metabolism and detection of four of the larger GHRH synthetic analogs (sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex) in fortified urine. Nineteen major in vitro metabolites were identif …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activ …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Growth hormone-releasing hormone and its analogues sermorelin, tesamorelin and CJC-1295 are included in the prohibited list of the World Antidoping Agency. These target peptides are found at very low concentrations in urine (at the pg/mL level). ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivativ …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS. Sample …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glu …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland. ...Using a pair of monoclonal antibodies raised against the CJC-1295 peptide, we present an immuno-polymerase chain reaction (I- …
2 represented evidence records
Years represented: 2015, 2016
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2015, 2024
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2021
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2006
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2020
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2026
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2019
Publishing organizations appearing in records: peer_reviewed_research